This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Innovative algorithms analyze gene biomarkers to provide predictive insights and personalized patient therapy. Point of Care Tests Point-of-care testing (POCT) quickly assesses cardiac biomarkers and other heart health indicators, aiding in prompt diagnosis and treatment decisions.
Current guidelines for implantable cardioverter defibrillators (ICD), primarily based on LV ejection fraction (LVEF) are sub-optimal and have limitations. Patients with ischemic heart disease (IHD) suffer an elevated risk of sudden cardiac death (SCD).
Protection against the increased risk of sudden cardiac death (SCD) due to ventricular arrhythmias is offered by the implantation of cardiac defibrillators. This is a single-centre retrospective study on the outcomes of all patients who had a transvenous defibrillator implant in 2015. Data from 235 patients were analysed.
Background:Serum troponins and CK-MB (creatine kinase-MB) are readily detectable and reliable cardiac-specific biomarkers of subclinical myocardial injury. Conclusions:Comprehensive evaluations of biomarkers of myocardial injury, cTnI and CK-MB, have considerable value for predicting adverse outcomes among patients with HCM.
Better stratification of risk, the researchers say, would help clinicians to identify people in need of an implantable cardioverter defibrillator (ICD) – a device that monitors heart rhythm and shocks the heart back into a normal rhythm if needed.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content